Welcome to our dedicated page for Veeva Systems news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Systems stock.
Veeva Systems Inc. (NYSE: VEEV) is a global leader in cloud-based software solutions specifically tailored for the life sciences industry. Headquartered in the San Francisco Bay Area, Veeva Systems provides innovative technology that helps pharmaceutical and biotech companies streamline their operations, ensure compliance, and bring products to market faster. Veeva's product offerings address key operational and regulatory needs, ranging from customer relationship management (CRM) to content management and data analytics.
Two of the company's flagship products include Veeva CRM and Veeva Vault. Veeva CRM is designed for companies with a salesforce, providing tools to manage customer interactions more efficiently. Meanwhile, Veeva Vault is a versatile content management platform that supports various functions such as clinical trials, regulatory submissions, and quality management within life sciences companies.
Veeva serves a diverse customer base, ranging from emerging biotechs to some of the world's largest pharmaceutical companies. Its commitment to product excellence, customer success, and continuous innovation is evident as Veeva frequently updates its offerings to meet the evolving needs of the industry. Recently, Veeva announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications to streamline clinical execution and improve regulatory management in its animal health business unit.
Another notable achievement for Veeva was the launch of the Veeva AI Partner Program, designed to help partners integrate Generative AI solutions seamlessly with Veeva Vault applications. This initiative highlights Veeva's ongoing efforts to leverage advanced technologies to enhance its product ecosystem. Furthermore, the introduction of Veeva Vault CRM Campaign Manager aims to simplify and speed up non-personal promotion to healthcare professionals, ensuring consistent and compliant marketing efforts.
Financially, Veeva Systems has shown strong performance with its fiscal year 2024 results reflecting robust growth. The company continues to invest in its innovation engine and strategic partnerships, setting the stage for sustained, profitable growth. Veeva's recent financial outlook for fiscal year 2025 and first quarter results for 2024 further underline its market leadership and operational excellence.
For more information about Veeva Systems, its products, and latest updates, visit www.veeva.com.
Veeva Systems (NYSE: VEEV) has entered a strategic partnership with Impel NeuroPharma to support the commercialization of Impel’s migraine treatment INP104, branded TRUDHESA™, pending FDA approval. The collaboration will enhance Impel's pre-launch efforts through Veeva's Commercial Cloud, ensuring a robust strategy for physician engagement and patient data management. TRUDHESA™ utilizes Impel's Precision Olfactory Delivery technology for effective drug delivery, optimizing treatment for migraines. This agreement marks a significant step toward addressing high unmet needs in CNS therapeutics.
Veeva Systems (NYSE: VEEV) has announced that six out of the seven largest global CROs have joined its Veeva Vault CDMS partner program, enhancing clinical data management capabilities industry-wide. This program aims to modernize clinical trials and improve trial performance through advanced technology. CROs such as Covance, ICON, Parexel, PPD, PRA Health Sciences, and Syneos Health will leverage Veeva's technology for faster and more efficient trials. The move supports the increasing need for speed and efficiency in clinical research.
Veeva Systems (NYSE: VEEV) announced that Epredia is implementing Veeva Vault Quality and Vault RIM applications to automate quality management and regulatory operations, enhancing efficiency in change control processes. This integration aims to improve collaboration, reduce manual overhead, and comply with diagnostic reporting regulations including 21 CFR part 820 and ISO13485. Notably, Epredia's adoption of Veeva's solutions is expected to streamline product lifecycle management and facilitate quicker market access for diagnostic products.
Veeva Systems (NYSE: VEEV) announced overwhelming shareholder support, with 99% approving its conversion to a public benefit corporation effective February 1, 2021. This makes Veeva the largest publicly traded company to adopt this model, which allows it to balance interests among stakeholders, including customers, employees, and shareholders. The change aligns with Veeva's mission to enhance productivity in the life sciences sector and create quality job opportunities. Additionally, a proposal to declassify its board received near unanimous approval.
Veeva Systems (NYSE: VEEV) announced that 99% of shareholders voted in favor of its proposal to become a public benefit corporation (PBC), effective Feb. 1, 2021. This conversion makes Veeva the largest publicly traded company to adopt such a status, maintaining its for-profit status while prioritizing the interests of multiple stakeholders. The decision aligns with Veeva's mission to enhance human health and ensures accountability to customers, employees, and shareholders. Additionally, shareholders approved a proposal to declassify the board of directors.
Veeva Systems (NYSE: VEEV) has partnered with Integra LifeSciences to implement Veeva Vault CDMS for their clinical trials. This solution enhances electronic data capture, coding, data cleaning, and reporting, leading to reduced database build times. Hugo Cervantes from Veeva highlighted the importance of flexibility and speed in MedTech trials, emphasizing how this partnership aims to innovate for better patient care. Veeva Vault CDMS is gaining traction across various sectors, making clinical research more efficient.
Veeva Systems (NYSE: VEEV) announced that Samsung Biologics has implemented Veeva Vault QMS to enhance its quality management processes. This integration complements Samsung's use of Veeva Vault QualityDocs, streamlining document control for improved visibility and compliance. With this upgrade, Samsung Biologics strengthens its quality processes across global operations, responding to evolving regulatory standards. James Choi, CIO of Samsung Biologics, emphasized the importance of unified quality management for effective manufacturing, highlighting the strategic partnership with Veeva to drive innovation.
Veeva Systems (NYSE: VEEV) announced that Simbec-Orion, a contract research organization, will implement the Veeva Vault CTMS and Veeva Vault eTMF to enhance clinical trial operations. This adoption aims to digitize workflows and improve real-time data sharing, boosting trial efficiency. Simbec-Orion's CIO noted that Veeva's solutions provide a digital foundation for effective clinical trials. The integration allows for better collaboration and compliance, ultimately accelerating trial execution while maintaining high-quality data for sponsors.
Veeva Systems (NYSE: VEEV) announced that GenesisCare Clinical CRO has integrated Veeva Vault eTMF, CTMS, and Payments into its operations to enhance trial processes globally. This partnership allows GenesisCare to utilize a secure cloud platform for streamlined drug development, enhancing efficiency in managing clinical studies. The integration aims to simplify data sharing, document management, and payment processes, contributing to quicker and more effective trial execution as GenesisCare expands its services.
Veeva Systems reported impressive growth in its fiscal third quarter ending October 31, 2020, with total revenues reaching $377.5 million, a 34% increase year-over-year. Subscription services revenues also rose 34% to $302.9 million. Operating income was $101.3 million, up 25%, while net income increased 18% to $97.0 million. The company provided guidance for Q4 revenues of $378-$380 million and fiscal year revenues of $1.446-$1.448 billion. Veeva emphasized ongoing digital transformation in life sciences as a driver of growth.
FAQ
What is the current stock price of Veeva Systems (VEEV)?
What is the market cap of Veeva Systems (VEEV)?
What does Veeva Systems Inc. do?
Where is Veeva Systems Inc. headquartered?
What are Veeva's main products?
Who are Veeva Systems' customers?
What recent partnerships has Veeva announced?
What is the Veeva AI Partner Program?
How has Veeva performed financially recently?
What is Veeva Vault CRM Campaign Manager?
What industry does Veeva Systems primarily serve?
How does Veeva contribute to the life sciences industry?
